Galimedix Therapeutics Presents New Preclinical Data on GAL-201 at AD/PD™ 2024 Conference

Galimedix Therapeutics, a biotechnology company in phase 2 clinical development, announced the presentation of new preclinical data regarding the molecule GAL-201, a modulator of beta-amyloid aggregation, in a transgenic model of Alzheimer's disease. These results will be presented at the International Conference on Alzheimer's and Parkinson's Diseases and Other Neurological Disorders (AD/PD™ 2024), which will be held March 5-9, 2024 in Lisbon, Portugal.

The poster entitled "The beta-amyloid aggregation modulator GAL-201 in development for the oral treatment of Alzheimer's disease: Cognitive improvement in a transgenic model of AD" will show the beneficial effects of GAL-201. This orally administered molecule has shown potential in preventing the formation of toxic forms of Aβ aggregates in the brain, thus offering hope for the treatment of Alzheimer's disease.

GAL-201, which is in the preclinical testing phase, is presented as a promising candidate for slowing or stopping the progression of Alzheimer's disease thanks to its ability to bind with high affinity the misfolded forms of Aβ, thus preventing their aggregation into toxic oligomers and protofibrils.